$17.18−0.43 (−2.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Immunome (IMNM) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
6 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 50% below its peak, net margin −3060.0%. Worth your attention in FY25: Share count (+49.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼23.2%
6.9
FY21→FY25CAGR —
Net income ($M)▲27.5%
−212.4
FY21→FY25CAGR —
Free cash flow ($M)▼70.1%
−200.6
FY21→FY25CAGR —
Diluted EPS▲51.4%
−2.43
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+49.0%
58.6mn → 87.4mn diluted shares since FY24. Rising share count dilutes EPS. Growth must outrun it.
Capex
$9.7M
+35.0% YoY in FY25 · 139.5% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-3060¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Operating Net
Net margin -3060.0% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7692, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 6,941.0 | 9,041.0 | 14,018.0 | 0.0 | 0.0 | ▼23.2% | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | —A | —A | —A | 0.0 | 0.0 | — | — |
Research & development | 236,542.0 | 187,286.0 | 281,886.0 | 103,891.0 | 23,272.0 | 14,110.0 | ▼33.6% | +90.9% |
Selling, general & admin | 64,147.0 | 43,768.0 | 32,955.0 | 19,657.0 | 13,629.0 | 11,094.0 | ▲32.8% | +40.9% |
Total operating expenses | 300,689.0 | 231,054.0 | 314,841.0 | 123,548.0 | 36,901.0 | 25,204.0 | ▼26.6% | +74.0% |
Operating incomefeeds ROC rank | −300,689.0 | −224,113.0 | −305,800.0 | −109,530.0 | −36,901.0 | −25,204.0 | ▲26.7% | — |
Other income, net | 18,040.0 | 11,719.0 | 12,837.0 | 2,724.0 | 5.0 | 493.0 | — | — |
Pretax income | −282,649.0 | −212,394.0 | −292,963.0 | −106,806.0 | −36,896.0 | −24,711.0 | ▲27.5% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −282,649.0 | −212,394.0 | −292,963.0 | −106,806.0 | −37,518.0 | −24,711.0 | ▲27.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −2.65 | −2.43 | −5.00 | −5.38 | −3.09 | −2.14 | ▲51.4% | — |
Diluted shares (mn) | 113.56 | 87.35 | 58.64 | 19.84 | 12.13 | 11.54 | ▲49.0% | +65.9% |
| Margins | ||||||||
Gross margin | — | —A | —A | —A | — | — | — | — |
Operating margin | — | −3228.8% | −3382.4% | −781.4% | — | — | ▲153.5pp | −2447.5pp |
Net margin | — | −3060.0% | −3240.4% | −761.9% | — | — | ▲180.4pp | −2298.1pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Immunome's revenue last fiscal year?
Immunome reported revenue of $6.9M in fiscal 2025, down 23.2% from fiscal 2024.
What was Immunome's net income?
Immunome reported net income of −$212.4M in fiscal 2025, a net margin of −3060.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

